BACKGROUND: Platelet concentrate transfusion is the standard treatment for hemato-oncology patients to compensate for thrombocytopenia. We have developed a novel platelet activation test in anticoagulated unprocessed blood (pac-t-UB) to determine platelet function in platelet concentrates and in blood of thrombocytopenic patients. METHODS: We have measured platelet activity in a platelet concentrate and in anticoagulated unprocessed blood of a post-transfusion thrombocytopenic patient. RESULTS: Our data show time-dependent platelet activation by GPVI agonist (collagen related peptide; CRP), PAR-1 agonist (SFLLRN), P2Y12 agonist (ADP), and thromboxane receptor agonist (U46619) in a platelet concentrate. Furthermore, pac-t-UB showed time-dependent platelet activation in unprocessed blood of a post-transfusion patient with thrombocytopenia. Testing platelet function by different agonists in relation to storage show that 3-day-old platelet concentrates are still reactive to the studied agonists. This reactivity rapidly drops for each agonists during longer storage. DISCUSSION: Pac-t-UB is a novel tool to estimate platelet function by different agonists in platelet concentrates and in unprocessed blood of thrombocytopenic patients. In the near future, we will validate whether pac-t-UB is an adequate test to monitor the quality of platelet concentrates and whether pac-t-UB predicts the bleeding risk of transfused thrombocytopenic patients.
BACKGROUND: Platelet concentrate transfusion is the standard treatment for hemato-oncologypatients to compensate for thrombocytopenia. We have developed a novel platelet activation test in anticoagulated unprocessed blood (pac-t-UB) to determine platelet function in platelet concentrates and in blood of thrombocytopenicpatients. METHODS: We have measured platelet activity in a platelet concentrate and in anticoagulated unprocessed blood of a post-transfusion thrombocytopenicpatient. RESULTS: Our data show time-dependent platelet activation by GPVI agonist (collagen related peptide; CRP), PAR-1 agonist (SFLLRN), P2Y12 agonist (ADP), and thromboxane receptor agonist (U46619) in a platelet concentrate. Furthermore, pac-t-UB showed time-dependent platelet activation in unprocessed blood of a post-transfusion patient with thrombocytopenia. Testing platelet function by different agonists in relation to storage show that 3-day-old platelet concentrates are still reactive to the studied agonists. This reactivity rapidly drops for each agonists during longer storage. DISCUSSION: Pac-t-UB is a novel tool to estimate platelet function by different agonists in platelet concentrates and in unprocessed blood of thrombocytopenicpatients. In the near future, we will validate whether pac-t-UB is an adequate test to monitor the quality of platelet concentrates and whether pac-t-UB predicts the bleeding risk of transfused thrombocytopenicpatients.
Authors: T C Van Holten; M Roest; J Riphagen; C Jansen; P Naarding; H J Adriaansen; P G De Groot; J A Remijn Journal: J Thromb Haemost Date: 2012-06 Impact factor: 5.824
Authors: Darrell J Triulzi; Susan F Assmann; Ronald G Strauss; P M Ness; John R Hess; Richard M Kaufman; Suzanne Granger; Sherrill J Slichter Journal: Blood Date: 2012-04-10 Impact factor: 22.113
Authors: Rutger A Middelburg; Mark Roest; Jannemieke Ham; Miriam Coccoris; Jaap Jan Zwaginga; Pieter F van der Meer Journal: Transfusion Date: 2012-12-07 Impact factor: 3.157
Authors: Tesse C Leunissen; Crystel M Gijsberts; Peter Paul Wisman; Albert Huisman; Maarten Ten Berg; Folkert W Asselbergs; Imo E Hoefer; Gerard Pasterkamp; Frans L Moll; Gert Jan de Borst; Mark Roest Journal: Int J Angiol Date: 2016-10-24
Authors: Sven Van Poucke; Dana Huskens; Kurt Van der Speeten; Mark Roest; Bart Lauwereins; Ming-Hua Zheng; Seppe Dehaene; Joris Penders; Abraham Marcus; Marcus Lancé Journal: PLoS One Date: 2018-06-21 Impact factor: 3.240
Authors: Dana Huskens; Yaqiu Sang; Joke Konings; Lisa van der Vorm; Bas de Laat; Hilde Kelchtermans; Mark Roest Journal: PLoS One Date: 2018-02-01 Impact factor: 3.240